By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile



Friedrich-Ebert-Str. 475
Building 302
Wuppertal    D-42117  Germany
Phone: 49-0-202-31763-0 Fax: 49-0-202-31763-1177



Company News
AiCuris Announces U.S. NIH Support Of Preclinical Study With AIC649 Against Chronic Hepatitis B 11/23/2016 1:52:44 PM
AiCuris Initiates Clinical Development For Topical Pritelivir, A Highly Active Inhibitor For The Treatment Of Herpes Simplex Virus 4/4/2016 9:00:45 AM
AiCuris' AIC649 Shows Potential To Induce Functional Cure Of Chronic Hepatitis B In Preclinical Study 1/5/2016 10:18:48 AM
AiCuris Strengthens Its Management 6/3/2015 9:40:09 AM
AiCuris And Merck & Co., Inc. (MRK) Announce Publication In New England Journal Of Medicine Of Phase 2 Clinical Trial Results Of Investigational Antiviral Agent Letermovir In Bone Marrow Transplant Patients 5/8/2014 10:54:18 AM
AiCuris Surpasses 50% Enrollment Milestone in Phase II Superiority Trial for Herpes Drug Pritelivir 1/29/2013 10:55:50 AM
Merck & Co., Inc. (MRK), AiCuris Ink $571 Million CMV Pact 10/30/2012 1:02:13 PM
AiCuris Promising Drugs Against Herpes Simplex (AIC316) and Human Cytomegalovirus (Letermovir, AIC246) in Preparation for Phase III 8/7/2012 10:39:46 AM
Results of AiCuris's Letermovir (AIC246) Phase 2b in Prophylaxis of Human Cytomegalovirus in Recipients of Human Blood Precursor Cell Transplants Meeting Both Primary Efficacy Endpoints to be Presented at International Conferences 4/2/2012 9:50:12 AM
AiCuris Drug Letermovir (AIC246) Meets Primary Efficacy Endpoints in Phase 2 For Human Cytomegalovirus (HCMV) Prophylaxis in Human Blood Precursor Cell Recipients 2/14/2012 9:50:00 AM